🔎 Trials Near Me

Utama › Glioblastoma › Ohio › Columbus

Kajian klinikal Glioblastoma di Columbus, OH

14 kajian untuk Glioblastoma sedang mencari peserta di lokasi dalam dan sekitar Columbus (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

Mengambil pesertaFasa 3
  • The Ohio State University, Columbus
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT07195591

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Mengambil pesertaFasa 1/2
  • Ohio State University Comprehensive Cancer Center, Columbus
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05432804

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Mengambil pesertaFasa 2
  • Ohio State University, Columbus
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07326566

Targeted Pediatric High-Grade Glioma Therapy

Mengambil pesertaKajian pemerhatian
  • Nationwide Children's Hospital, Columbus
12 Months – 39 Years · Semua jantina · Dikemas kini 8 Sep 2026 · NCT05839379

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Mengambil pesertaFasa 1
  • Ohio State University Comprehensive Cancer Center, Columbus
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06860594

Study of Olutasidenib and Temozolomide in HGG

Mengambil pesertaFasa 2
  • Nationwide Children's Hospital, Columbus
Umur 12 hingga 39 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT06161974

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Mengambil peserta
  • Ohio State University Medical Center, Columbus
Umur 18 hingga 85 · Semua jantina · Dikemas kini 21 Jul 2026 · NCT06910306

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

Mengambil pesertaFasa 2
  • Ohio State University, Columbus
Umur 18 hingga 80 · Semua jantina · Dikemas kini 17 Jul 2026 · NCT07225621

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Mengambil pesertaFasa 2
  • The Ohio State University Comprehensive Cancer Center, Columbus
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Jul 2026 · NCT06805305

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Mengambil pesertaFasa awal 1Sukarelawan sihat dialu-alukan
  • Nationwide Children's Hospital, Columbus
Umur 1 hingga 21 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT06333899

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Mengambil pesertaFasa 1/2
  • Ohio State University Hospital, Columbus
Umur 18 hingga 70 · Semua jantina · Dikemas kini 12 Jun 2026 · NCT07346144

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Mengambil pesertaFasa 2
  • Nationwide Children's Hospital, Columbus
12 Months – 39 Years · Semua jantina · Dikemas kini 29 Mei 2026 · NCT05843253

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Mengambil pesertaFasa 1/2
  • Ohio State University Comprehensive Cancer Center, Columbus
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Apr 2026 · NCT06810544

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Mengambil pesertaKajian pemerhatian
  • Massive Bio SYNERGY-AI site, Columbus
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Kajian Glioblastoma di bandar lain

Kajian lain di Columbus

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.